BAROS EFFERVESCENT GRANULES 420 MG
TARTARIC ACID : 420 MG SODIUM BICARBONATE : 460 MG · DIN 00776580 · TYCO HEALTHCARE
Health Canada status: CANCELLED POST MARKET
What is BAROS EFFERVESCENT GRANULES?
BAROS EFFERVESCENT GRANULES 420 MG contains TARTARIC ACID : 420 MG SODIUM BICARBONATE : 460 MG. It is listed in the Health Canada Drug Product Database under DIN 00776580, held by TYCO HEALTHCARE, supplied as POWDER (EFFERVESCENT) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 07-Jan-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00776580 |
|---|---|
| Brand name | BAROS EFFERVESCENT GRANULES |
| Generic / active ingredient | TARTARIC ACID : 420 MG SODIUM BICARBONATE : 460 MG |
| Manufacturer | TYCO HEALTHCARE |
| Strength | 420 MG |
| Dosage form | POWDER (EFFERVESCENT) |
| Route of administration | ORAL |
| Schedule | Ethical |
| ATC code | V07AY OTHER NON-THERAPEUTIC AUXILIARY PRODUCTS |
| AHFS class | 36:89.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 07-Jan-2010 |
| Original market date | 1988-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code V07AY OTHER NON-THERAPEUTIC AUXILIARY PRODUCTS. 0 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DISCLOSE DRY HANDLE SWAB | 1.5 % | SWAB | BEUTLICH L.P. | CANCELLED POST MARKET | DIN 02242509 |
| E-Z-GAS 2 GRANULES | 1.808 G / 4 G | POWDER | THERAPEX DIVISION DE E-Z-EM CANADA INC | CANCELLED POST MARKET | DIN 01990047 |
| MC METHYLCELLULOSE SOLUTION 1% | 1 G / 100 ML | SOLUTION | E-Z-EM INC. | CANCELLED POST MARKET | DIN 00603198 |
| UNIK ZORU PWR | 1.05 G / 3 G | POWDER | THERAPEX DIVISION DE E-Z-EM CANADA INC | CANCELLED POST MARKET | DIN 00514594 |
| UNIK ZORU TAB | 52.5 MG | TABLET | THERAPEX DIVISION DE E-Z-EM CANADA INC | CANCELLED POST MARKET | DIN 00514586 |
Who else supplies OTHER NON-THERAPEUTIC AUXILIARY PRODUCTS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OTHER NON-THERAPEUTIC AUXILIARY PRODUCTS appears in 8 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.